Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia

Abstract Background Since 2017, the first-line treatment for uncomplicated Plasmodium falciparum infection in Ethiopia has been artemether-lumefantrine (AL), plus a single dose of primaquine (PQ). The World Health Organization (WHO) recommends regular monitoring of the first-line drug efficacy as cr...

Full description

Saved in:
Bibliographic Details
Main Authors: Bontu Abate, Bokretsion Gidey Brhane, Tsegahun Manyazewal, Hussien Mohammed, Yonas Wuletaw, Moges Kassa, Mesay Hailu, Getachew Tollera, Geremew Tasew, Ashenafi Assefa, Eyasu Makonnen
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Malaria Journal
Subjects:
Online Access:https://doi.org/10.1186/s12936-025-05337-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850057355275796480
author Bontu Abate
Bokretsion Gidey Brhane
Tsegahun Manyazewal
Hussien Mohammed
Yonas Wuletaw
Moges Kassa
Mesay Hailu
Getachew Tollera
Geremew Tasew
Ashenafi Assefa
Eyasu Makonnen
author_facet Bontu Abate
Bokretsion Gidey Brhane
Tsegahun Manyazewal
Hussien Mohammed
Yonas Wuletaw
Moges Kassa
Mesay Hailu
Getachew Tollera
Geremew Tasew
Ashenafi Assefa
Eyasu Makonnen
author_sort Bontu Abate
collection DOAJ
description Abstract Background Since 2017, the first-line treatment for uncomplicated Plasmodium falciparum infection in Ethiopia has been artemether-lumefantrine (AL), plus a single dose of primaquine (PQ). The World Health Organization (WHO) recommends regular monitoring of the first-line drug efficacy as crucial tool for supporting national treatment policies. This study aimed to assess the efficacy of AL with single dose of PQ for the treatment of uncomplicated P. falciparum malaria. Methods A prospective single-arm efficacy study was conducted among outpatients at Shecha Health Centre, aged six months and older with confirmed uncomplicated P. falciparum malaria from October 2023 to January 2024. Participants were treated with AL plus single dose of PQ and followed up to 28 days to evaluate clinical and parasitological responses. Kaplan–Meier (KM) survival analysis and per protocol (PP) analysis were used to estimate primary and secondary outcomes. Paired sample t-test was used to compare mean haemoglobin levels across follow-up dates (SPSS v.25). All comparisons were made at 95% confidence interval (CI), with a level of significance at 0.05. Results A total of 93 patients with uncomplicated P. falciparum were enrolled and 88 participants completed the study. Based on KM analysis the overall PCR uncorrected cure rate of AL plus single dose of PQ was 96.6% (95% CI 90.4–99.3%). The PCR-corrected cure rate was 100% (95% CI 95.8–100%). Despite high cure rate, accompanied by fast resolution of clinical symptoms, 17% of participants continued to have detectable parasitaemia on day 3. There was a slight decrease in mean haemoglobin on day 28 compared to the baseline. No serious adverse events were reported during the 28-day follow-up period. Conclusion The study findings reaffirm high efficacy of AL with a single dose of PQ for the treatment of uncomplicated P. falciparum malaria, with acceptable safety profile. These findings support the ongoing use of AL with a single dose of PQ as the primary treatment option for uncomplicated P. falciparum infections in the study area. In the context of the emergence and spread of partial artemisinin-based combination therapy(ACT) resistance in Africa, regular monitoring of the efficacy of current artemisinin-based combinations is recommended for the early detection of emerging drug resistance in the study setting and beyond.
format Article
id doaj-art-e893aef482224af98611a73da850f22a
institution DOAJ
issn 1475-2875
language English
publishDate 2025-03-01
publisher BMC
record_format Article
series Malaria Journal
spelling doaj-art-e893aef482224af98611a73da850f22a2025-08-20T02:51:27ZengBMCMalaria Journal1475-28752025-03-0124111210.1186/s12936-025-05337-2Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest EthiopiaBontu Abate0Bokretsion Gidey Brhane1Tsegahun Manyazewal2Hussien Mohammed3Yonas Wuletaw4Moges Kassa5Mesay Hailu6Getachew Tollera7Geremew Tasew8Ashenafi Assefa9Eyasu Makonnen10Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa UniversityEthiopian Public Health Institute (EPHI)Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa UniversityEthiopian Public Health Institute (EPHI)Ethiopian Public Health Institute (EPHI)Ethiopian Public Health Institute (EPHI)Ethiopian Public Health Institute (EPHI)Ethiopian Public Health Institute (EPHI)Ethiopian Public Health Institute (EPHI)Ethiopian Public Health Institute (EPHI)Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa UniversityAbstract Background Since 2017, the first-line treatment for uncomplicated Plasmodium falciparum infection in Ethiopia has been artemether-lumefantrine (AL), plus a single dose of primaquine (PQ). The World Health Organization (WHO) recommends regular monitoring of the first-line drug efficacy as crucial tool for supporting national treatment policies. This study aimed to assess the efficacy of AL with single dose of PQ for the treatment of uncomplicated P. falciparum malaria. Methods A prospective single-arm efficacy study was conducted among outpatients at Shecha Health Centre, aged six months and older with confirmed uncomplicated P. falciparum malaria from October 2023 to January 2024. Participants were treated with AL plus single dose of PQ and followed up to 28 days to evaluate clinical and parasitological responses. Kaplan–Meier (KM) survival analysis and per protocol (PP) analysis were used to estimate primary and secondary outcomes. Paired sample t-test was used to compare mean haemoglobin levels across follow-up dates (SPSS v.25). All comparisons were made at 95% confidence interval (CI), with a level of significance at 0.05. Results A total of 93 patients with uncomplicated P. falciparum were enrolled and 88 participants completed the study. Based on KM analysis the overall PCR uncorrected cure rate of AL plus single dose of PQ was 96.6% (95% CI 90.4–99.3%). The PCR-corrected cure rate was 100% (95% CI 95.8–100%). Despite high cure rate, accompanied by fast resolution of clinical symptoms, 17% of participants continued to have detectable parasitaemia on day 3. There was a slight decrease in mean haemoglobin on day 28 compared to the baseline. No serious adverse events were reported during the 28-day follow-up period. Conclusion The study findings reaffirm high efficacy of AL with a single dose of PQ for the treatment of uncomplicated P. falciparum malaria, with acceptable safety profile. These findings support the ongoing use of AL with a single dose of PQ as the primary treatment option for uncomplicated P. falciparum infections in the study area. In the context of the emergence and spread of partial artemisinin-based combination therapy(ACT) resistance in Africa, regular monitoring of the efficacy of current artemisinin-based combinations is recommended for the early detection of emerging drug resistance in the study setting and beyond.https://doi.org/10.1186/s12936-025-05337-2EfficacySafetyArtemether-lumefantrinePlasmodium-falciparumEthiopia
spellingShingle Bontu Abate
Bokretsion Gidey Brhane
Tsegahun Manyazewal
Hussien Mohammed
Yonas Wuletaw
Moges Kassa
Mesay Hailu
Getachew Tollera
Geremew Tasew
Ashenafi Assefa
Eyasu Makonnen
Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia
Malaria Journal
Efficacy
Safety
Artemether-lumefantrine
Plasmodium-falciparum
Ethiopia
title Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia
title_full Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia
title_fullStr Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia
title_full_unstemmed Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia
title_short Increasing day three parasitaemia is observed after treatment of patients with artemether-lumefantrine and single dose of primaquine for uncomplicated Plasmodium falciparum malaria in Arbaminch Zuria district, Southwest Ethiopia
title_sort increasing day three parasitaemia is observed after treatment of patients with artemether lumefantrine and single dose of primaquine for uncomplicated plasmodium falciparum malaria in arbaminch zuria district southwest ethiopia
topic Efficacy
Safety
Artemether-lumefantrine
Plasmodium-falciparum
Ethiopia
url https://doi.org/10.1186/s12936-025-05337-2
work_keys_str_mv AT bontuabate increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia
AT bokretsiongideybrhane increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia
AT tsegahunmanyazewal increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia
AT hussienmohammed increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia
AT yonaswuletaw increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia
AT mogeskassa increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia
AT mesayhailu increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia
AT getachewtollera increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia
AT geremewtasew increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia
AT ashenafiassefa increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia
AT eyasumakonnen increasingdaythreeparasitaemiaisobservedaftertreatmentofpatientswithartemetherlumefantrineandsingledoseofprimaquineforuncomplicatedplasmodiumfalciparummalariainarbaminchzuriadistrictsouthwestethiopia